Evaluation of MGIT 960™ and the colorimetric-based method for tuberculosis drug susceptibility testing

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 9, 2010, Pages 1169-1175

  Morcillo, Nora ^a   Imperiale, B ^a,b   Di Giulio, B ^c  

^a Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c Petrona V de Cordero Hospital   (Argentina)

Author keywords

Colorimetric methods; Drug susceptibility; MGIT 960; Tuberculosis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ARGENTINA; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; COLORIMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG SENSITIVITY; EVALUATION; GOLD STANDARD; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM GROWTH INDICATOR TUBE SYSTEM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTITUBERCULAR AGENTS; ARGENTINA; BACTERIOLOGICAL TECHNIQUES; COLORIMETRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS;

EID: 77956566528     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis control: surveillance, planning, finances. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2006.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
3. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
4. Gandhi N R, Moll A, Sturm A W, et al. Extensive drug-resistant tuberculosis as a cause of death in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
5. Matteelli A, Migliori G B, Cirillo D, Centis R, Girardi E, Raviglione M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis epidemiology and control. Expert Rev Anti Infect Ther 2007; 5: 857-871.
6. Dorman S E, Chaisson R E. From magic bullets to the magic mountain. The rise of extensively drug-resistant tuberculosis. Nat Med 2007; 13: 295-298.
7. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. WHO/HTM/TB.2008.402. Geneva, Switzerland: WHO, 2008.
9. World Health Organization. Green Light Committee Initiative. Frequently asked questions. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/ challenges/mdr/greenlightcommittee/en/index.html Accessed April 2009.
10. Heifets L B. In: Heifets L B, ed. Drug susceptibility test in the management of chemotherapy of tuberculosis. Boca Raton, FL, USA: CRC Press, 1991: pp 89-121.
11. Burgos M, DeRiemer K, Small P M, et al. Effects on drug resistance on the generation of secondary cases of tuberculosis. J Inf Dis 2003; 188: 1878-1884.
12. Ralph A P, Anstey N M, Kelly P M. Tuberculosis in the 2010s: is the glass half full? Clin Infect Dis 2009; 49: 574-583.
13. Bonilla C A, Crossa A, Jave H O, et al. Management of extensively drug-resistance in Peru: cure is possible. PLoS ONE 2008; 3e 2957.
14. Morcillo N, Imperiale B, Corral J. [Pediatric tuberculosis, MDR and XDR-TB in Buenos Aires Province during the period 2002-2007]. Rev Am Med Resp 2009; 9: 5-13. [Spanish]
15. Becton Dickinson and Company. BD BACTEC MGIT 960 SIRE kits for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Sparks, MD, USA: BD, 2005.
16. Bemer P, Palikova F, Rüsch-Gerdes S, Drugeon H B, Pfyffer G E. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-154.
17. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of susceptibility testing of the BACTEC MGIT 960 technology for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
18. Krüüner A, Yates M D, Drobniewski F A. Evaluation of MGIT 960-based antimicrobial susceptibility testing and determination of critical concentrations of first and second-line antimicrobial drugs with clinical drug-resistant strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-818.
19. Foongladda S, Roengsanthia D, Arjrattanakool W, Chuchottaworn C, Chairprasert A, Franzblau S G. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2002; 6: 1118-1122.
20. Martin A, Morcillo N, Lemus D, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2005; 9: 901-906.
21. Pontino M V, Di Giulio B, Fernandez C, Imperiale B, Bodon A, Morcillo N. Evaluation of a colorimetric micromethod for determining the minimal inhibitory concentration of antibiotics against Mycobacterium tuberculosis. Rev Arg Microbiol 2006; 38: 145-151.
22. Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino J C. Comparative evaluation of the nitrate reduction assay, the MTT test, and the reazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 55: 500-505.
23. Morcillo N, Di Giulio B, Testani B, Pontino M, Chirico C, Dolmann A. A microplate indicator-based method for determining the susceptibility of multidrug-resistant M. tuberculosis to anti-microbial agents. Int J Tuberc Lung Dis 2004; 8: 253-259.
24. Martin A, Camacho M, Palomino J C, Portaels F. Resarzurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-3619.
25. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
26. National Committee for Clinical and Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardia and other aerobic actinomycetes. Tentative standard. 2nd ed. Wayne, PA, USA: NCCLS, 2000.
27. McNeil B J, Hanley J A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984; 4: 137-150.
28. Raviglione M C, Smith I M. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356: 656-659.
29. World Health Organization. New World Health Organization policies. The use of liquid medium for culture and DST in middle- and low-income countries. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/dots/laboratory/policy/en/ index3.html Accessed April 2009.
30. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176: 637-642.
31. Alito A, Morcillo N, Scipioni S, et al. The IS6110 restriction fragment length polymorphism in particular multidrug-resistant Mycobacterium tuberculosis strains may evolve too fast for reliable use in outbreak investigation. J Clin Microbiol 1999; 37: 788-791.
32. Burgos M, Gonzalez L C, Paz E A, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975.
33. Martin A, von Groll A, Fissette K, Palomino J C, Varaine F, Portaels F. Rapid detection of M. tuberculosis resistance to second-line drugs by use of the manual Mycobacterium Growth Indicator Tube system. J Clin Microbiol 2008; 46: 3952-3956.
34. Lin S Y, Desmond E, Bonato D, Gross W, Siddiqi S. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009; 47: 3630-3634.
35. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger E C. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-1780.